National Vaccine Panel to Recommend Suspending AstraZeneca Shots for Under 55s

A vial of the AstraZeneca COVID-19 vaccine is seen with injection supplies at a clinic in Winnipeg, on March 19, 2021. John Woods / The Canadian Press

OTTAWA—Health Canada is demanding that AstraZeneca do a detailed study on the risks and benefits of its COVID-19 vaccine across multiple age groups after getting more reports that patients in Europe developed blood clots following vaccination.

The agency says it has not received any reports of blood clots in Canada to date.